SERSigth Solutions is a science-driven Tech-based-startup focused on transforming cervical cancer diagnostics through an innovative, minimally invasive blood-based test enabled by advanced Surface-Enhanced Raman Spectroscopy (SERS) substrates.
Our business emerges in response to a major unmet need across Latin America and globally: the lack of accessible, comfortable, and early-stage screening methods for cervical cancer.

Our proprietary surface-enhanced Raman scattering (SERS) substrates provide unprecedented sensitivity for detecting cervical cancer biomarkers.

Our product meets this need by enabling molecular-level detection of biomarkers associated with pre-cancerous lesions, tumor progression, treatment resistance, and post-remission monitoring. Unlike the Pap smear, which relies on morphological evaluation of already altered cells, our blood-based method detects changes before visible damage occurs.
This positions SERSIGHT Solutions as a high-value player within the global Femtech and women's health diagnostics sectors